NEW YORK (GenomeWeb News) – Compugen today said that Teva Pharmaceutical industries has exercised its option to utilize in its research activities a combination of biomarkers discovered by the firm for early detection of drug-induced nephrotoxicity.
The biomarkers were discovered under a collaboration between the two firms in 2007. Compugen used its computational tools, discovery engines, and nucleic acid testing platforms, as well as data from Teva, in a preclinical study.
Teva has a royalty-free right to use the biomarkers for internal research and development efforts, while Compugen retained the commercialization rights for licensing such markers to other firms and rights to use the biomarkers internally. Compugen noted that it intends to commercially launch the biomarkers through licensing arrangements during the second half of this year.